Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
17.20
-1.18 (-6.40%)
Mar 31, 2025, 10:47 AM EDT - Market open

Company Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.

Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc.
Immunovant logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 207
CEO Peter Salzmann

Contact Details

Address:
320 West 37th Street, 6th Floor
New York, New York 10018
United States
Phone 917 580 3099
Website immunovant.com

Stock Details

Ticker Symbol IMVT
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001764013
CUSIP Number 45258J102
ISIN Number US45258J1025
Employer ID 83-2771572
SIC Code 2836

Key Executives

Name Position
Dr. Peter Salzmann M.B.A., M.D. Chief Executive Officer and Director
Dr. Frank M. Torti M.B.A., M.D. Executive Chairperson of the Board
Dr. Jay S. Stout Ph.D. Chief Technology Officer
Eva Renee Barnett M.B.A. Chief Financial Officer
Melanie Gloria B.S.N. Chief Operating Officer
Christopher A. Van Tuyl Esq., J.D. Chief Legal Officer and Corporate Secretary
Lauren Schrier M.B.A. Vice President of Marketing
Christine Blodgett Senior Vice President of Human Resources
Andy Deig Senior Vice President of Strategic Finance
Dr. Michael Geffner M.B.A., M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 SCHEDULE 13G Filing
Mar 19, 2025 8-K Current Report
Mar 7, 2025 144 Filing
Mar 7, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 144 Filing
Feb 11, 2025 144 Filing
Feb 6, 2025 10-Q Quarterly Report
Feb 6, 2025 8-K Current Report
Jan 24, 2025 8-K Current Report
Jan 24, 2025 424B3 Prospectus